News & Events

SUNNYVALE, CA -- (Marketwired) -- 10/21/16 -- Viveve Medical, Inc.'s (NASDAQ: VIVE) wholly-owned subsidiary, Viveve, Inc. ("Viveve"), a medical technology company focused on women's health, today filed a patent infringement lawsuit against ThermiGen, LLC, ThermiAesthetics, LLC, and Dr. Red Alinsod in U.S. District Court for the Eastern District of Texas. The lawsuit seeks redress for the Defendants' unauthorized use of Viveve's patented technology. The action is intended to protect Viveve's significant investment in reverse-thermal gradient radiofrequency technology and its clinical application to tightening vaginal tissue. Viveve is pursuing all available remedies, including an injunction to prevent the Defendants from selling, training, and promoting its infringing products and treatment methods.

The lawsuit is based on U.S. Patent No. 8,961,511 entitled "Vaginal Remodeling Device and Methods." The patent covers methods for remodeling tissue of the vagina and vulva by applying heat to the target tissue. ThermiGen, LLC, ThermiAesthetics, LLC, and Dr. Red Alinsod are accused of willfully infringing Viveve's patent.
"Viveve has invested heavily in our technology and patents. We intend to monitor activities and vigorously protect our intellectual property estate as needed," said Patricia Scheller, chief executive officer of Viveve.

About Viveve
Viveve Medical, Inc. is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The Viveve System has received regulatory approval in many countries throughout the world and is available through physician import license in Japan.

Safe Harbor Statement
All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Viveve® is a registered trademark of Viveve, Inc.

Investor Relations contact: 
Amato and Partners, LLC 
90 Park Avenue, 17th Floor
New York, NY 10016
[email protected]

Media contact:
Jessica Burns
Berry & Company Public Relations
(212) 253-8881
[email protected]
Source: Viveve Medical, Inc.